EA202090344A1 - МОНО- И БИСПЕЦИФИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С hERG1 И hERG1/ИНТЕГРИНОМ БЕТА 1 - Google Patents

МОНО- И БИСПЕЦИФИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С hERG1 И hERG1/ИНТЕГРИНОМ БЕТА 1

Info

Publication number
EA202090344A1
EA202090344A1 EA202090344A EA202090344A EA202090344A1 EA 202090344 A1 EA202090344 A1 EA 202090344A1 EA 202090344 A EA202090344 A EA 202090344A EA 202090344 A EA202090344 A EA 202090344A EA 202090344 A1 EA202090344 A1 EA 202090344A1
Authority
EA
Eurasian Patent Office
Prior art keywords
herg1
mono
specific antibodies
integrin
antibodies binding
Prior art date
Application number
EA202090344A
Other languages
English (en)
Inventor
Аннароза Арканджели
Клаудиа Дуранти
Лаура Каррарези
Сильвиа Крешоли
Original Assignee
Университа Дельи Студи Ди Фиренце
Ди.В.А.Л. Тоскана С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университа Дельи Студи Ди Фиренце, Ди.В.А.Л. Тоскана С.Р.Л. filed Critical Университа Дельи Студи Ди Фиренце
Publication of EA202090344A1 publication Critical patent/EA202090344A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Настоящее изобретение описывает биспецифическое антитело, состоящее из вариабельных доменов (VH и VL) двух антител, mAb против hERG1 (который связывает внеклеточный домен S5-P hERG1) и mAb против 1-интегрина TS2/16 или BV7, которые связывают внеклеточный домен 1-интегрина. Настоящее изобретение относится также к новой анти-hERG1 молекуле, несущей Cys в положении 95 домена VH. Изобретение описывает также их применение в диагностических и терапевтических целях в онкологии и других областях медицинских наук.
EA202090344A 2017-07-21 2018-06-29 МОНО- И БИСПЕЦИФИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С hERG1 И hERG1/ИНТЕГРИНОМ БЕТА 1 EA202090344A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000083637A IT201700083637A1 (it) 2017-07-21 2017-07-21 Nuovi anticorpi
PCT/EP2018/067641 WO2019015936A1 (en) 2017-07-21 2018-06-29 MONO AND BISPECIFIC ANTIBODIES BINDING TO HERG1 AND HERG1 / INTEGRIN BETA 1

Publications (1)

Publication Number Publication Date
EA202090344A1 true EA202090344A1 (ru) 2020-06-08

Family

ID=60570110

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090344A EA202090344A1 (ru) 2017-07-21 2018-06-29 МОНО- И БИСПЕЦИФИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С hERG1 И hERG1/ИНТЕГРИНОМ БЕТА 1

Country Status (10)

Country Link
US (1) US11572406B2 (ru)
EP (1) EP3655434A1 (ru)
JP (1) JP7378088B2 (ru)
KR (1) KR20200104279A (ru)
CN (1) CN111479827B (ru)
AU (1) AU2018302356A1 (ru)
CA (1) CA3070643A1 (ru)
EA (1) EA202090344A1 (ru)
IT (1) IT201700083637A1 (ru)
WO (1) WO2019015936A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120022116A1 (en) * 2010-07-20 2012-01-26 Huayun Deng Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
HUE046306T2 (hu) 2014-01-07 2020-02-28 Colorobbia Italiana Spa Katekollal funkcionalizált mágneses nanorészecskék, elõállításuk és alkalmazásuk
EP3177647B1 (en) * 2014-08-08 2018-10-10 Universita' Degli Studi di Firenze Anti-herg1 antibodies

Also Published As

Publication number Publication date
CN111479827A (zh) 2020-07-31
IT201700083637A1 (it) 2019-01-21
EP3655434A1 (en) 2020-05-27
AU2018302356A1 (en) 2020-03-05
CA3070643A1 (en) 2019-01-24
KR20200104279A (ko) 2020-09-03
US20210147574A1 (en) 2021-05-20
US11572406B2 (en) 2023-02-07
WO2019015936A1 (en) 2019-01-24
JP7378088B2 (ja) 2023-11-13
JP2020534023A (ja) 2020-11-26
CN111479827B (zh) 2024-03-05

Similar Documents

Publication Publication Date Title
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
PH12019501014A1 (en) Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
BR112019005670A2 (pt) anticorpos anti-muc16 (mucina 16)
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
MA45712A (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
IL265541B1 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
WO2016191246A3 (en) T cell receptor-like antibodies specific for a prame peptide
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
NI201400019A (es) Anticuerpo anti-alfabetatcr
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
MX2015004105A (es) Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso.
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
MX2017011252A (es) ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD.
MX2016004928A (es) Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus.
NZ709828A (en) Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MX2017009680A (es) Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы